Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.

Reiss, Allison B et al.·Biomolecules·2025·low-moderateReview
RPEP-13234Reviewlow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
low-moderate
Sample
N=Not applicable (review)
Participants
Adults with obesity using GLP-1 agonists for weight loss

What This Study Found

GLP-1 agonists reduce body weight by 15-25% over about one year, but most patients regain weight after stopping. The review discusses strategies for safe discontinuation while maintaining weight loss.

Key Numbers

40% of adults worldwide are overweight, 13% are obese. GLP-1 drugs reduce body weight by 15-25% after about 1 year. Boxed warning for medullary thyroid carcinoma and MEN2 history.

How They Did This

Narrative review of GLP-1 agonist mechanisms, efficacy, adverse effects, and discontinuation strategies for obesity treatment.

Why This Research Matters

Weight regain after stopping GLP-1 drugs is one of the biggest challenges in obesity treatment. Finding ways to taper off these medications without losing progress is critical for long-term success.

What This Study Doesn't Tell Us

Review article without original data. No proven discontinuation protocols exist. Long-term data on weight maintenance after stopping are limited. Newer agents have very short track records.

Trust & Context

Original Title:
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.
Published In:
Biomolecules, 15(3) (2025)
Database ID:
RPEP-13234

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13234·https://rethinkpeptides.com/research/RPEP-13234

APA

Reiss, Allison B; Gulkarov, Shelly; Lau, Raymond; Klek, Stanislaw P; Srivastava, Ankita; Renna, Heather A; De Leon, Joshua. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.. Biomolecules, 15(3). https://doi.org/10.3390/biom15030408

MLA

Reiss, Allison B, et al. "Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.." Biomolecules, 2025. https://doi.org/10.3390/biom15030408

RethinkPeptides

RethinkPeptides Research Database. "Weight Reduction with GLP-1 Agonists and Paths for Discontin..." RPEP-13234. Retrieved from https://rethinkpeptides.com/research/reiss-2025-weight-reduction-with-glp1

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.